This trial is evaluating whether Encorafenib will improve 5 primary outcomes and 56 secondary outcomes in patients with BRAF V600E-mutant Metastatic Colorectal Cancer. Measurement will happen over the course of Cycle 1 (up to 28 days).
This trial requires 702 total participants across 3 different treatment groups
This trial involves 3 different treatments. Encorafenib is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Recent findings shows that CRC affects about 1 million people yearly in the US. Nearly 6,000 CRC patients in the year 2013 will have [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer)s located in the colon. Cancer Research"
"Aglaia leptocephala\n\nAglaia leptocephala is a species of plant in the family Meliaceae." - Anonymous Online Contributor
"There is a strong hereditary component to colorectal cancer, but in the majority of cases, the disease develops in the context of other factors, the most important of which are smoking, stress and infection." - Anonymous Online Contributor
"Therapies for colorectal cancer differ according to whether it is localized (in situ) or has spread (metastatic). Common therapies include surgical staging, chemotherapy, immunotherapy, radiation therapy, and targeted therapies. There is considerable inconsistency regarding use of adjuvant therapies." - Anonymous Online Contributor
"CRC has a cure rate of 90% in early-stage disease, and an increasing cure rate with further stages of the disease. There is also an increasing cure rate if a proximal colon cancer is encountered. Early detection and a well-planned approach may prevent the disease progressing to a terminal course." - Anonymous Online Contributor
"It is common for colorectal cancer to go undetected. Most people (74%) have colorectal cancer symptoms before diagnosis and 80% will have symptoms after surgery and chemotherapy. The most common symptoms are bleeding from the rectum and weight loss. Other symptoms include pain in the gastrointestinal tract, an inability to drink fluids or have bowel movements and a change in bowel habit which may be related to more serious conditions." - Anonymous Online Contributor
"Although most deaths from [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) result from another health condition, roughly 10% of deaths from colorectal cancer are attributable to the cancer itself. The colorectal cancer screening programme in Taiwan is an effective and low-cost way to achieve this goal." - Anonymous Online Contributor
"About 40% of colorectal cancers are diagnosed at age 50 or less. This emphasizes the importance of screening for colorectal cancers in patients over age 50." - Anonymous Online Contributor
"Patients with familial adenomatous polyposis or hereditary non-polyposis colorectal carcinoma have an approximately 20-50% chance of developing [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) by age 50. The cumulative risk for persons with microalbuminuria of developing colorectal cancer by age 70 is approximately 5%. People with early onset of colon cancer (patients who have their first cancers before age 45) have a 5-10% chance of development of colorectal cancer by age 70. This information would be useful for patients and their physicians whenever making decisions to screen colon cancer patients more frequently or less frequently." - Anonymous Online Contributor
"This review summarizes the major controversies associated with the staging and grading systems of colorectal cancer and provides new insights about the spread of colorectal cancer." - Anonymous Online Contributor
"There is good evidence that encorafenib is effective in treating patients with advanced [soft tissue sarcoma](https://www.withpower.com/clinical-trials/soft-tissue-sarcoma)s and melanoma. Recent findings provide a basis for further testing it as part of combination therapy for advanced colorectal cancer. Clinically complete response rates are lower than those in advanced sarcomas and melanoma, reflecting the difficulty in obtaining a complete response. It is expected that trials comparing combination therapies incorporating encorafenib alone versus encorafenib with chemotherapy will provide the best evidence as to its role in colon cancer." - Anonymous Online Contributor
"Encorafenib was effective in treatment of people with unresectable or metastatic well differentiated colorectal cancer. The high response observed in our study is in keeping with recent data from clinical trials on the molecular targeted agents that have been approved for use in colorectal cancer. Encorafenib showed higher response rates for complete radiologic response than for partial response." - Anonymous Online Contributor
"The majority of patients presenting with metastatic colorectal carcinoma experienced a favourable response to the drug. Encorafenib is active in patients with previously treated metastatic colorectal cancer, even in those with a progressive disease history, with good tolerability." - Anonymous Online Contributor